Nuveen LLC Makes New Investment in Ocular Therapeutix, Inc. $OCUL

Key Points

• Nuveen LLC acquired 414,104 shares of Ocular Therapeutix, valued at approximately $3,035,000, making it a notable new investor in the company.
• Ocular Therapeutix reported a quarterly revenue of $13.46 million, which exceeded analyst expectations despite a year-over-year decline of 17.7% in revenue.
• Analysts generally have a "Buy" rating for Ocular Therapeutix, with a consensus price target of $17.20 following various price adjustments from firms like Needham & Company and Scotiabank.

Nuveen LLC purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 414,104 shares of the biopharmaceutical company's stock, valued at approximately $3,035,000. Nuveen LLC owned 0.26% of Ocular Therapeutix at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new stake in Ocular Therapeutix in the 4th quarter valued at $28,000. GAMMA Investing LLC raised its holdings in shares of Ocular Therapeutix by 6,760.0% in the first quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 8,112 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Ocular Therapeutix by 2,045.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock valued at $76,000 after buying an additional 8,446 shares during the last quarter. Vontobel Holding Ltd. bought a new position in shares of Ocular Therapeutix in the first quarter valued at about $79,000. Finally, Freestone Grove Partners LP bought a new position in shares of Ocular Therapeutix in the fourth quarter valued at about $119,000. Institutional investors own 59.21% of the company's stock.

Ocular Therapeutix Trading Up 3.9%

Shares of OCUL stock traded up $0.48 on Tuesday, reaching $12.69. The company had a trading volume of 971,827 shares, compared to its average volume of 1,789,068. The company has a current ratio of 10.10, a quick ratio of 10.02 and a debt-to-equity ratio of 0.23. The stock has a market cap of $2.21 billion, a PE ratio of -9.86 and a beta of 1.50. The company has a 50-day moving average of $11.38 and a 200-day moving average of $8.90. Ocular Therapeutix, Inc. has a 12 month low of $5.78 and a 12 month high of $12.91.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). The company had revenue of $13.46 million during the quarter, compared to the consensus estimate of $13.12 million. Ocular Therapeutix had a negative net margin of 382.51% and a negative return on equity of 71.92%. The business's revenue was down 17.7% compared to the same quarter last year. During the same period last year, the company earned ($0.26) earnings per share. On average, equities analysts forecast that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Insider Activity at Ocular Therapeutix

In related news, insider Jeffrey S. Heier sold 3,063 shares of the business's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $12.04, for a total value of $36,878.52. Following the completion of the transaction, the insider directly owned 259,911 shares in the company, valued at approximately $3,129,328.44. The trade was a 1.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Peter Kaiser sold 3,011 shares of the business's stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $12.04, for a total value of $36,252.44. Following the completion of the transaction, the insider owned 204,093 shares of the company's stock, valued at $2,457,279.72. This represents a 1.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 29,453 shares of company stock worth $354,614. 2.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on OCUL. Scotiabank cut their price target on Ocular Therapeutix from $22.00 to $20.00 and set a "sector outperform" rating for the company in a report on Wednesday, August 6th. Needham & Company LLC lifted their price target on Ocular Therapeutix from $14.00 to $15.00 and gave the company a "buy" rating in a report on Tuesday, August 5th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a report on Thursday, May 29th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Ocular Therapeutix presently has a consensus rating of "Buy" and a consensus price target of $17.20.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.